Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial

被引:64
作者
Soriano, Vincent [1 ]
Garcia-Gasco, Pilar [1 ]
Vispo, Eugenia [1 ]
Ruiz-Sancho, Andres [1 ]
Blanco, Francisco [1 ]
Martin-Carbonero, Luz [1 ]
Rodriguez-Novoa, Sonia [2 ]
Morello, Judit [2 ]
De Mendoza, Carmen [3 ]
Rivas, Pablo [1 ]
Barreiro, Pablo [1 ]
Gonzalez-Lahoz, Juan [1 ]
机构
[1] Hosp Carlos III, Dept Infect Dis, E-28029 Madrid, Spain
[2] Hosp Carlos III, Pharmacokinet Unit, E-28029 Madrid, Spain
[3] Hosp Carlos III, Virol Lab, E-28029 Madrid, Spain
关键词
antiretroviral therapy; simplification strategies; drug resistance; metabolic syndrome; dyslipidaemia;
D O I
10.1093/jac/dkm413
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Atazanavir seems to be a protease inhibitor (PI) with a more favourable metabolic profile. Information regarding the potential benefit of replacing lopinavir/ritonavir by atazanavir in HIV-infected patients with prolonged viral suppression is scarce. If proved, this strategy could be particularly attractive for the subset of patients with greater cardiovascular risk. Methods: SLOAT was a prospective, open, comparative trial in which patients receiving lopinavir/ritonavir-based regimens and having undetectable plasma HIV-RNA for longer than 24 weeks were randomized to continue on the same therapy or switch to atazanavir. Outcomes in viral rebound, CD4 counts, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides and glucose were compared in both groups of patients at 48 weeks of follow-up. Results: A total of 189 patients were recruited and took at least the first dose of the assigned treatment arm. Overall, 102 switched to atazanavir (49 on 400 mg once daily, and 53 on 300 mg plus 100 mg of ritonavir once daily due to concomitant tenofovir use) and 87 continued on lopinavir/ritonavir. All patients received the PI along with two nucleoside analogues. Virological failure occurred in 12 patients switched to atazanavir and 9 continuing on lopinavir/ritonavir. A reduction (P < 0.001) in median total cholesterol (-19 mg/dL) and triglycerides (-80 mg/dL) was observed after 48 weeks of atazanavir switching, whereas no significant changes occurred in the lopinavir/ritonavir arm. Greater reductions in total cholesterol and triglycerides were seen in patients switched to atazanavir without ritonavir boosting. Conclusions: The replacement of lopinavir/ritonavir by atazanavir provides an overall significant reduction in total cholesterol and triglycerides, without increased risk of virological failure.
引用
收藏
页码:200 / 205
页数:6
相关论文
共 21 条
[1]   An update on therapeutic drug monitoring for antiretroviral drugs [J].
Back, David ;
Gibbons, Sara ;
Khoo, Saye .
THERAPEUTIC DRUG MONITORING, 2006, 28 (03) :468-473
[2]   Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir [J].
Bongiovanni, M ;
Bini, T ;
Cicconi, P ;
Landonio, S ;
Meraviglia, P ;
Testa, L ;
Di Biagio, A ;
Chiesa, E ;
Tordato, F ;
Biasi, P ;
Adorni, F ;
Monforte, AD .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (02) :132-138
[3]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[4]   Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial [J].
Cohen, C ;
Nieto-Cisneros, L ;
Zala, C ;
Fessel, WJ ;
Gonzalez-Garcia, J ;
Gladysz, A ;
McGovern, R ;
Adler, E ;
McLaren, C .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (10) :1683-1692
[5]   Mitigation of anti retroviral-induced hyperlipidernia by hepatitis C virus co-infection [J].
Cooper, Curtis L. ;
Mills, Edward ;
Angel, Jonathan B. .
AIDS, 2007, 21 (01) :71-76
[6]   Combination antiretroviral therapy and the risk of myocardial infarction [J].
Friis-Moller, N ;
Sabin, CA ;
Weber, R ;
Monforte, AD ;
El-Sadr, WM ;
Reiss, P ;
Thiébaut, R ;
Morfeldt, L ;
De Wit, S ;
Pradier, C ;
Calvo, G ;
Law, MG ;
Kirk, O ;
Phillips, AN ;
Lundgren, JD ;
Lundgren, JD ;
Weber, R ;
Monteforte, AD ;
Bartsch, G ;
Reiss, P ;
Dabis, F ;
Morfeldt, L ;
De Wit, S ;
Pradier, C ;
Calvo, G ;
Law, MG ;
Kirk, O ;
Phillips, AN ;
Houyez, F ;
Loeliger, E ;
Tressler, R ;
Weller, I ;
Friis-Moller, N ;
Sabin, CA ;
Sjol, A ;
Lundgren, JD ;
Sawitz, A ;
Rickenbach, M ;
Pezzotti, P ;
Krum, E ;
Meester, R ;
Lavignolle, V ;
Sundström, A ;
Poll, B ;
Fontas, E ;
Torres, F ;
Petoumenos, K ;
Kjær, J ;
Hammer, S ;
Neaton, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :1993-2003
[7]   Class of antiretroviral drugs and the risk of myocardial infarction [J].
Friis-Moller, Nina ;
Reiss, Peter ;
Sabin, Caroline A. ;
Weber, Rainer ;
Monforte, Antonella d'Arminio ;
El-Sadr, Wafaa ;
De Wit, Stephane ;
Kirk, Ole ;
Fontas, Eric ;
Law, Matthew G. ;
Phillips, Andrew ;
Lundgren, Jens D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (17) :1723-1735
[8]   Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN study (AI424-097) 48-week results [J].
Gatell, Jose ;
Salmon-Ceron, Dominique ;
Lazzarin, Adriano ;
Van Wijngaerden, Eric ;
Antunes, Francisco ;
Leen, Clifford ;
Horban, Andrzej ;
Wirtz, Victoria ;
Odeshoo, Linda ;
Van den Dungen, Monique ;
Gruber, Claudia ;
Ledesma, Emilio .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (11) :1484-1492
[9]   Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection [J].
Howard, Andrea A. ;
Lo, Yungtai ;
Floris-Moore, Michelle ;
Klein, Robert S. ;
Fleischer, Norman ;
Schoenbaum, Ellie E. .
AIDS, 2007, 21 (05) :633-641
[10]   96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures [J].
Johnson, M ;
Grinsztejn, B ;
Rodriguez, C ;
Coco, J ;
DeJesus, E ;
Lazzarin, A ;
Lichtenstein, K ;
Wirtz, V ;
Righmire, A ;
Odeshoo, L ;
McLaren, C .
AIDS, 2006, 20 (05) :711-718